BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.4% – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price traded down 3.4% during mid-day trading on Tuesday . The company traded as low as $7.65 and last traded at $7.66. 84,786 shares changed hands during trading, a decline of 96% from the average session volume of 2,174,724 shares. The stock had previously closed at $7.93.

Wall Street Analyst Weigh In

BCRX has been the topic of a number of recent research reports. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Needham & Company LLC raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday. Evercore ISI boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.17.

BioCryst Pharmaceuticals Price Performance

The business has a 50-day moving average price of $7.59 and a two-hundred day moving average price of $7.61. The firm has a market cap of $1.46 billion, a PE ratio of -11.57 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. The business’s revenue was up 35.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.19) EPS. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently bought and sold shares of BCRX. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,322 shares during the last quarter. DRW Securities LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $74,000. Xponance Inc. raised its stake in BioCryst Pharmaceuticals by 13.1% in the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,505 shares during the last quarter. Quantinno Capital Management LP purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at about $82,000. Finally, SkyView Investment Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.